Evaluation of Screening and Risk Reducing Surgery for Women Followed in a High Risk Breast/Ovarian Cancer Clinic
ACOG ePoster. Stewart M. Apr 27, 2018; 212125; 25A
Martha Stewart
Martha Stewart
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Introduction: Up to 20% of ovarian cancers are attributed to inherited predispositions, however current screening methods (Ca-125 and pelvic ultrasound) do not improve outcomes compared to risk-reducing (RR) surgery. The study objective was to evaluate surgical outcomes of women followed in an academic center's High-Risk Breast/Ovarian Cancer (HBOC) clinic following RR surgery.

Methods: Retrospective chart review of women from the past decade who underwent RR surgery in a HBOC clinic. Surgical outcomes, pathology, pre-operative screening results, and pre-/post-operative cancer diagnoses were evaluated.

Results: One hundred and eighty-six high risk women were identified with a mean age of 50.2 years and a mean BMI of 28.9 kg/m2 at the time of surgery. The majority (106; 57%) had strong family history of ovarian cancer without an identified mutation but the rest had deleterious mutations (BRCA2-17.7%, BRCA1-15.1%, Lynch 3.2%, or p53 0.5%). The most common procedure was a risk-reducing bilateral salpingo-oophorectomy with or without hysterectomy (RRBSO, 88.7%). All women underwent the SEE-FIM protocol with extensive pathologic analysis which found 2 (0.8%) invasive ovarian cancers (1 ovary/tube carcinosarcoma, 1 granulosa cell), 3 (1.6%) serous tubal intraepithelial carcinomas (STIC), and 1 fallopian tube cancer (0.8%). All tubal pathology was diagnosed in women with documented BRCA mutations. No cancers were found on screening.

Conclusion/Implications: Among all high-risk women undergoing RR surgery, about 3% are ultimately diagnosed with a STIC or an ovarian cancer of which none were identified on screening. All STIC and tubal cancers were diagnosed in women with BRCA mutations (6.6% rate).
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings